
|Videos|January 8, 2019
Expert Addresses Major Challenge in Treatment of Myeloma
Author(s)David M. Siegel, MD, PhD
David M. Siegel, MD, PhD, discusses one of the biggest dilemmas to arise recently in the treatment of multiple myeloma.
Advertisement
David S. Siegel, MD, PhD, chief of the division of multiple myeloma at John Theurer Cancer Center, Hackensack Meridian Health, discusses one of the biggest dilemmas to arise recently in the treatment of multiple myeloma.
According to Siegel, there is a notion that it is imperative to change classes of drugs when there is progression of disease. This is believed by both community oncologists and myeloma experts alike.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
Dr Tolaney on SG + Pembrolizumab Biomarker Data in First-Line mTNBC
3
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
4
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
5

































